Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI) Meeting Abstract
| Authors: | Lang, J. M.; Tagawa, S. T.; Slovin, S.; Sperger, J. M.; Schehr, J. L.; Stahlfeld, C.; Hintz, A. M.; Emamekhoo, H.; Rathkopf, D.; Abida, W.; Autio, K.; Xiao, H.; Mitchell, A.; Molina, A. M.; Zhao, S. G.; Eickhoff, J.; Dehm, S.; Nanus, D. M.; Kyriakopoulos, C. |
| Abstract Title: | Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI) |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S993 |
| End Page: | S994 |
| Language: | English |
| ACCESSION: | WOS:001326612902270 |
| DOI: | 10.1016/j.annonc.2024.08.1729 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1648P -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
